Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-HG MR spectroscopy in low-grade glioma patients treated with vorasidenib
NL-OMON56925Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vorasidenib in glioma and brain neoplasm, sponsored by University Medical Center Groningen. Primary endpoint: Association between preoperative 2-HG concentration and progression-free time. Started Aug 2024; status: recruiting.
02
Drugs
vorasidenib
03
Conditions
gliomabrain neoplasm
Beyond the preview
Go deeper on NL-OMON56925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56925.